Tech Company Financing Transactions
LevitasBio Funding Round
LevitasBio secured a $35 million Series C funding round on 11/7/2022. Backers included Novalis LifeSciences, Decheng Capital and Pavilion Capital.
Transaction Overview
Company Name
Announced On
11/7/2022
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its commercial efforts through the development of instruments for sample processing and analysis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1505 Adams Dr. D
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
LevitasBio is unlocking a new dimension in cellular analysis. Our mission is to advance science and human health by providing researchers with a new and powerful method of cellular analysis. While the last decade has seen tremendous advancement in analytical tools for genomics and proteomics such as next-generation sequencing, single cell genomics, and even phenotypic imaging down to single-cell resolution, there had been no innovation in the sample preparation and cellular analysis market for decades -- until now.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Pieprzyk
Vice President
Gang Sun
VP - Engineering
Geoff Facer
VP - Finance
Joe Walthers
VP - General Counsel
Steven Collier
VP - Operations
Mike Lee
VP - R & D
Kevin Travers
Browse more venture capital transactions:
Prev: 11/7/2022: VoltAero venture capital transaction
Next: 11/7/2022: EdgeDB venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs